A trial looking at lanreotide autogel for neuroendocrine tumours of the digestive system that have spread

This trial looked at a drug called lanreotide autogel to stop or slow the growth of neuroendocrine tumours (NETs). It was for people with NETs that couldn’t be removed with an operation or had spread to another part of the body from where it started.

Neuroendocrine tumours are a rare group of cancers that make and release hormones. They normally start in the digestive system but can sometimes appear elsewhere in the body.

Lanreotide autogel is a man made form of a hormone called somatostatin. Doctors already use it to treat a type of neuroendocrine tumour called carcinoid tumour.